U. Landmesser Et Al. , "2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia," EUROPEAN HEART JOURNAL , vol.39, no.14, pp.1131-1143, 2018
Landmesser, U. Et Al. 2018. 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. EUROPEAN HEART JOURNAL , vol.39, no.14 , 1131-1143.
Landmesser, U., Chapman, M. J., Stock, J. K., Amarenco, P., Belch, J. J. F., Boren, J., ... Farnier, M.(2018). 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. EUROPEAN HEART JOURNAL , vol.39, no.14, 1131-1143.
Landmesser, Ulf Et Al. "2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia," EUROPEAN HEART JOURNAL , vol.39, no.14, 1131-1143, 2018
Landmesser, Ulf Et Al. "2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia." EUROPEAN HEART JOURNAL , vol.39, no.14, pp.1131-1143, 2018
Landmesser, U. Et Al. (2018) . "2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia." EUROPEAN HEART JOURNAL , vol.39, no.14, pp.1131-1143.
@article{article, author={Ulf Landmesser Et Al. }, title={2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia}, journal={EUROPEAN HEART JOURNAL}, year=2018, pages={1131-1143} }